Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma
Main Authors: | Pinato, D, Brown, M, Trousil, S, Aboagye, E, Beaumont, J, Zhang, H, Coley, H, Mauri, F, Sharma, R |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Springer Nature
2019
|
Similar Items
-
The Receptor Tyrosine Kinase AXL in Cancer Progression
by: Erinn B. Rankin, et al.
Published: (2016-11-01) -
Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma
by: Kristina Breitenecker, et al.
Published: (2023-09-01) -
Quantitative Tyrosine Phosphoproteome Profiling of AXL Receptor Tyrosine Kinase Signaling Network
by: Xinyan Wu, et al.
Published: (2021-08-01) -
A Receptor Tyrosine Kinase Inhibitor Sensitivity Prediction Model Identifies AXL Dependency in Leukemia
by: Ahmad Nasimian, et al.
Published: (2023-02-01) -
Altered expression of AXL receptor tyrosine kinase in gastrointestinal cancers: a promising therapeutic target
by: Nataliya Pidkovka, et al.
Published: (2023-07-01)